EYBELIS

This brand name is authorized in Japan

Active ingredients

The drug EYBELIS contains one active pharmaceutical ingredient (API):

1 Omidenepag UNII G0G0H52U6K - OMIDENEPAG ISOPROPYL
Omidenepag is a relatively selective EP2 receptor agonist which decreases intraocular pressure (IOP). The exact mechanism of action is unknown. Elevated IOP represents a major risk factor for glaucomatous field loss. Read about Omidenepag

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
S01EX06		S Sensory organs → S01 Ophthalmologicals → S01E Antiglaucoma preparations and miotics → S01EX Other antiglaucoma preparations
Discover more medicines within S01EX06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: JP	医薬品医療機器総合機構	Identifier(s): 1319764Q1027, 1319764Q2023

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.